构建体系化的研发矩阵。不久前，随着石碧院士、陈卫院士双院士工作站落地东阿阿胶，一场围绕阿胶 的现代科学解析加速展开。从阿胶原料的标准化研究到大健康领域的深度研究，传统中药的密码，正被 一步步破译。这不仅是两个院士工作站的落地，更是一个立体化创新体系逐渐成型的缩影——东阿阿胶 将其称为"一中心三高地+N联合"研发创新体系。以获批的国家胶类中药工程技术研究中心为核心，打 造"原料涵养研发高地"、"滋补中药研发高地"、"健康消费品研发高地"。同时，与中国农业大学、四川 大学、江南大学、中国科学院大连化学物理研究所等超过40所高校和科研院所展开深度合作，形成了强 大的创新网络。 中医药学是中华民族的伟大创造，是中国古代科学的瑰宝。推动中医药传承创新发展，是时代赋予的命 题。国务院办公厅印发的《关于提升中药质量促进中医药产业高质量发展的意见》明确提出，要加快推 进中药产业转型升级。 面对新的发展要求，传统中药企业如何破局而立，向"新"而行? 以东阿阿胶股份有限公司(以下简称"东阿阿胶")为代表的一批老字号企业，正以生动的实践作答。根据 东阿阿胶年报，其营业收入从2021年的38.49亿元稳健增长至2024年的59.21 ...

Core Viewpoint - Dong'e Ejiao reported steady growth in its 2025 semi-annual results, with significant improvement in operating cash flow compared to the first quarter [1][2]. Financial Performance - The company achieved operating revenue of 3.051 billion yuan, a year-on-year increase of 11.02% [1]. - Net profit attributable to shareholders reached 818 million yuan, up 10.74% year-on-year [1]. - The net profit after deducting non-recurring gains and losses was 788 million yuan, reflecting a 12.58% increase [1]. - The net cash flow from operating activities was 965 million yuan, a growth of 4.70% [1][2]. Market Position and Strategy - Dong'e Ejiao, a leading enterprise in the traditional Chinese medicine industry, has maintained a growth trend in recent years, supported by the expanding market for traditional Chinese medicine [2]. - The company is implementing the "1238" strategy to enhance its core business and explore potential products, focusing on the integration of the gel industry chain [1][4]. - Dong'e Ejiao's two core products, Dong'e Ejiao blocks and compound Ejiao syrup, hold nearly 40% market share in the qi and blood supplement category, with Dong'e Ejiao blocks dominating at approximately 70% market share [4]. Dividend Policy - The company announced a dividend plan to distribute 817 million yuan to shareholders, representing 99.94% of the net profit for the period [3]. - Since its first dividend in 1999, Dong'e Ejiao has cumulatively distributed 10.104 billion yuan, demonstrating stable long-term dividend capability [3]. Growth Initiatives - Dong'e Ejiao is actively developing its "second growth curve" with brands like "Royal Weichang 1619" and "Zhuangben," targeting the men's health market [5][6]. - The "Royal Weichang 1619" brand has seen over 150% revenue growth, with its flagship product achieving a 666% increase year-on-year [5]. - The "Zhuangben" brand, launched in late 2024, has quickly gained traction, focusing on a product matrix that meets consumer needs [6]. Future Outlook - The company plans to continue its dual-driven growth model of pharmaceuticals and health consumer products, reinforcing the value of its core products while expanding its men's health product matrix [6].

Core Insights - The company is transforming its traditional manufacturing processes through smart manufacturing and AI technology, enhancing efficiency and product quality [1][2] - Financial performance shows significant growth, with revenue increasing from 3.849 billion to 5.921 billion and net profit rising from 440 million to 1.557 billion from 2021 to 2024 [1] - The company is focusing on digital transformation of its supply chain, which has led to an increase in gross margin from 47.57% in 2019 to 72.42% in 2024 [2] Digital Transformation and Product Development - The company is implementing AI-driven quality control and IoT-based environmental monitoring to enhance manufacturing capabilities [2] - New product lines such as "Peach Blossom Princess" and "Dong'e Ejiao Little Gold Bar" are expanding market reach and catering to consumer preferences [2] - The company is targeting the male health market, developing products like Ejiao and Cistanche raw liquid to create a comprehensive product matrix [2][3] Future Strategy and R&D Focus - The company plans to integrate primary, secondary, and tertiary industries to enhance resource supply, product innovation, and cultural tourism [3] - Five key R&D areas have been identified: innovation in gelatin-based medicines, major variety cultivation, new drug development, health consumer product development, and leading the donkey industry [3] - Increased investment in R&D and the establishment of a high-standard innovation system are priorities to enhance core competitiveness [3]